CSIMarket Company Name, Ticker, Industry, else..
 
Marker Therapeutics inc   (NASDAQ: MRKR)
 
Price: $1.1400 $-0.03 -2.564%
Day's High: $1.1799999475479126 Week Perf: -5 %
Day's Low: $ 1.14 30 Day Perf: -1.72 %
Volume (M): 35,858 52 Wk High: $ 2.46
Volume (M$): $ 0 52 Wk Avg: $1.35
Open: $1.17 52 Wk Low: $0.84



 Market Capitalization (Millions $) 22
 Shares Outstanding (Millions) 19
 Employees 5
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -9
 Cash Flow (TTM) (Millions $) 4
 Capital Exp. (TTM) (Millions $) 0

Business Description


Marker Therapeutics Inc. is a clinical-stage biotechnology company that specializes in the development and commercialization of immunotherapies for the treatment of various cancers. The company's patented MultiTAA T-cell therapy technology platform is designed to stimulate the patient's own immune system to target and destroy cancer cells. Marker Therapeutics aims to improve patient outcomes by utilizing personalized immunotherapies that have the potential to be more effective and have fewer side effects than traditional cancer treatments.


   Company Address: 2450 Holcombe Blvd, TMC Partners Office 1.311 Houston 77021 TX
   Company Phone Number: 400-6400   Stock Exchange / Ticker: NASDAQ MRKR


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ADCT   -13.93%    
MDGL   -3.21%    
NRIX   -4.23%    
RYTM   -3.02%    
SUPN   -1.64%    
ZYME   -3.35%    
• View Complete Report
   



Shares

Marker Therapeutics Secures $16.1 Million to Drive Lymphoma Breakthrough, Illuminating New Horizons in Cancer Treatment,

Published Thu, Dec 19 2024 1:07 PM UTC

Strategic Infusion: Marker Therapeutics’ $16.1 Million Private Placement Fuels Hope for Lymphoma TreatmentMarker Therapeutics, a frontrunner in the realm of cell therapies, has announced a significant milestone with a private placement of $16.1 million. This strategic financing marks a pivotal step in advancing their clinical endeavors, particularly for the Phase 1 APOLLO ...
Product Service News

Promising Advances in Lymphoma Treatment Clinical Success of MT-601 by Marker Therapeutics

Published Thu, Dec 19 2024 1:06 PM UTC

In the realm of oncology, breakthroughs in treatment options can significantly alter the landscape of patient care and outcomes. A recent clinical update from Marker Therapeutics Inc. highlights encouraging developments in the treatment of lymphoma, particularly through their investigational therapy, MT-601. Situated within the ongoing APOLLO study, a significant share of pa...
Product Service News

Preliminary Data from Marker Therapeutics APOLLO Study Presented at the 11th Global Summit on Hematologic Malignancies

Published Mon, Apr 8 2024 11:01 AM UTC

The 11th Global Summit on Hematologic Malignancies held in Whistler, BC, Canada, served as a platform for leading experts in the field to discuss and share the latest advancements in the treatment of blood cancers. Among the distinguished speakers was a principal investigator from the prestigious City of Hope National Medical Center, who presented groundbreaking clinical dat...
Product Service News

Marker Therapeutics Earns Key Approval for MT-601 Under the New Name, Neldaleucel, Amid Financial Setbacks

Published Mon, Jan 22 2024 12:30 PM UTC

HOUSTON, Jan. 22, 2024. Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company, has achieved a significant scientific milestone, even as it contends with financial setbacks. The advanced biotech firm, dedicated to developing next-generation T cell-based immunotherapies, has announced that its leading product candidate has received crucial approval...
Product Service News

Traversing Bumpy Financial Terrain, Marker Therapeutics Eyes Revolutionary Cancer Treatments with MT-601.

Published Mon, Jan 8 2024 1:25 PM UTC

Marker Therapeutics, a leading bio-pharmaceutical firm, recently announced vital updates and strategic prioritization of its clinical programs with concentrated focus on MT-601 in patients diagnosed with lymphoma. This move is prompted by a series of significant advancements as well as the necessity to tap into promising therapeutic areas that embody the potential to oversha...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 7.13
Price to Sales (Expected) -
Price to Book 1.81
PEG (TTM) -

Financial Strength Current
Quick Ratio 9.1
Working Capital Ratio 10.87
Leverage Ratio (MRQ) 0.2
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -0.48 $
Revenues (TTM) 0.16 $
Cash Flow (TTM) 0.2 $
Cash 1.14 $
Book Value 0.63 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -1,741,476
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.